Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978356 | 1.00 | CA12 (0.49) | CA12CA9KDM4EALDH1A1BLM | |
| SCHEMBL29445560 | 0.81 | CA12 (0.43) | CA12CA9KDM4EALDH1A1RECQL | |
| SCHEMBL28686883 | 0.81 | CA12 (0.43) | CA12CA9KDM4EALDH1A1RECQL | |
| SCHEMBL1114643 | 0.80 | CA12 (0.55) | CA12CA9KDM4EALDH1A1BLM | |
| SCHEMBL28596100 | 0.78 | CA12 (0.43) | CA12CA9KDM4EALDH1A1BCHE | |
| SCHEMBL28594343 | 0.78 | CA12 (0.43) | CA12CA9KDM4EALDH1A1BCHE | |
| SCHEMBL23646037 | 0.77 | BCHE (0.69) | KDM4EALDH1A1BLMTDP1POLB | |
| SCHEMBL1137647 | 0.75 | CA12 (0.43) | CA12CA9KDM4EALDH1A1MAPT | |
| SCHEMBL1135824 | 0.72 | GRIN2D (0.49) | KDM4EALDH1A1BLMTDP1POLB | |
| SCHEMBL19713074 | 0.72 | CA12 (0.50) | CA12CA9KDM4EALDH1A1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | LOHSE OLIVIER (FR) | 2012-08-30 | — | — | US | claimed |
| JP-4726778-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1613599-B8 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2011-06-22 | — | — | EP | claimed |
| EP-1613599-B1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | claimed |
| EP-1791820-B1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | claimed |
| US-7605267-B2 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2009-10-20 | — | — | US | claimed |
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | LOHSE OLIVIER | 2009-02-26 | — | — | US | claimed |
| EP-1791820-A2 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | Novartis AG (CH) | 2007-06-06 | — | — | EP | claimed |
| JP-2006522055-A | — | — | 2006-09-28 | — | — | JP | claimed |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2006-08-24 | — | — | US | claimed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | claimed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | claimed |
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| WO-2003042164-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003042160-A1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1107954-A1 | 2-OXO-$i(2H)-QUINOLINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012479-A1 | 2-OXO-2H-QUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447485-B2 | Class of bifunctional compounds with quanternary ammonium salt structure | AGTR2, AGTR1, ADRB2 | CA12 2597/4885CA9 3433/4885KDM4E 3505/4885 |
| US-20090054653-A1 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | HAX1, OPRK1, OPRD1 | CA12 4380/4885CA9 3811/4885KDM4E 1913/4885 |
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | OPRM1, OPRD1, HAX1 | CA12 4307/4885CA9 3977/4885KDM4E 2180/4885 |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | UGT8, KAT8, UGT1A8 | CA12 508/4885CA9 97/4885KDM4E 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.